Why the study?
Does continuous infusion of doxorubicin reduce cardiotoxicity in pediatric cancer patients compared to rapid infusion?
Does continuous infusion of doxorubicin reduce cardiotoxicity in pediatric cancer patients compared to rapid infusion?
Continuous infusion of doxorubicin significantly reduces the incidence of cardiotoxicity and mortality in pediatric cancer patients compared to rapid infusion.
No takes yet. Share an insight, caveat, or question.
May support lower cardiotoxicity with continuous doxorubicin in children; hypothesis-generating and requires randomized confirmation.
Berrak et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: